
    
      To assess the safety and efficacy of MEBO in the treatment of 14 subjects with VLUs. Subjects
      meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of
      treatment with either MEBO or SOC (7 subjects per treatment arm).
    
  